OncoMatch/Clinical Trials/NCT06150157
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Is NCT06150157 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including JNJ-88549968 and Ruxolitinib for neoplasms.
Treatment: JNJ-88549968 · Ruxolitinib · Momelotinib — The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968 in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s) in part 2 (Cohort Expansion). For U.S. sites: the purpose of this study is to characterize the safety and to determine the RP2D(s) and optimal dosing schedule(s) of JNJ-88549968 in Part 1 and part 1b (Dose Escalation), and to characterize the safety of JNJ-88549968 at the RP2D(s) in Part 2 and part 2b (Cohort Expansion), when given as monotherapy in essential thrombocythemia (ET) or myelofibrosis (MF), and with ruxolitinib or momelotinib in MF only.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: CALR driver mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogenic stem cell transplant
Exception: allowed if >6 months before first dose and no evidence of GVHD requiring immunosuppressant therapy
Prior treatment with allogenic stem cell transplant less than or equal to (<=) 6 months before the first dose of JNJ-88549968 or evidence of graft versus host disease (GVHD) that requires immunosuppressant therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- UCHealth Cancer Care Anschutz Medical Campus University of Colorado Cancer Center · Aurora, Colorado
- Moffit Cancer center · Tampa, Florida
- University of Michigan · Ann Arbor, Michigan
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify